Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | HTR7 | P34969 | 1/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659314 | 1.00 | ADORA1 (0.71) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL10866451 | 0.87 | ADORA1 (0.76) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL6659887 | 0.85 | ADORA1 (0.55) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL14903066 | 0.84 | ADORA1 (0.84) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL12265125 | 0.83 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL13276118 | 0.83 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL2248193 | 0.83 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL21033426 | 0.83 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL10608249 | 0.83 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A | |
| SCHEMBL14829269 | 0.83 | ADORA1 (1.00) | ADORA1ADORA3ADORA2AADORA2BHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1030856-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | claimed |
| US-6740644-B2 | ADENOSINE DERIVATIVES, AGONISTS AT THE ADENOSINE A1 RECEPTOR | SMITHKLINE BEECHAM CORPORATION | 2004-05-25 | — | — | US | claimed |
| US-20030158146-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158146-A1 | Chemical compounds | CNR1, ADORA3, ADORA1 | ADORA1 3/4885ADORA3 2/4885ADORA2A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.